Anthem Biosciences Ltd
Incorporated in 2006, Anthem Biosciences
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
- Market Cap ₹ 43,317 Cr.
- Current Price ₹ 771
- High / Low ₹ 874 / 702
- Stock P/E 95.9
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 28.5 %
- ROE 20.8 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 21.0%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | |
| 451 | 695 | 666 | 626 | 914 | 1,173 | |
| Operating Profit | 182 | 408 | 565 | 431 | 506 | 672 |
| OPM % | 29% | 37% | 46% | 41% | 36% | 36% |
| 21 | 37 | 49 | 139 | 63 | 85 | |
| Interest | 20 | 17 | 10 | 9 | 10 | 11 |
| Depreciation | 62 | 62 | 58 | 64 | 82 | 89 |
| Profit before tax | 121 | 366 | 546 | 497 | 477 | 657 |
| Tax % | 23% | 26% | 26% | 23% | 23% | 31% |
| 93 | 271 | 406 | 385 | 367 | 451 | |
| EPS in Rs | 110.62 | 319.74 | 462.09 | 6.75 | 6.57 | 8.07 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 14% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 4% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 21% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 114 | 112 | 112 |
| Reserves | 413 | 693 | 1,346 | 1,627 | 1,813 | 2,298 |
| 159 | 100 | 35 | 126 | 239 | 113 | |
| 207 | 232 | 228 | 148 | 235 | 284 | |
| Total Liabilities | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 |
| 306 | 361 | 329 | 449 | 483 | 705 | |
| CWIP | 50 | 19 | 154 | 164 | 345 | 297 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 |
| 333 | 445 | 863 | 902 | 1,099 | 1,373 | |
| Total Assets | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 166 | 278 | 333 | 306 | 140 | 418 | |
| -109 | -196 | -205 | -376 | -221 | -152 | |
| -48 | -63 | 181 | 64 | -77 | -134 | |
| Net Cash Flow | 9 | 18 | 308 | -6 | -158 | 133 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 61 | 84 | 97 | 95 | 126 | 89 |
| Inventory Days | 186 | 29 | 52 | 139 | 129 | 167 |
| Days Payable | 87 | 50 | 50 | 77 | 61 | 54 |
| Cash Conversion Cycle | 160 | 63 | 99 | 156 | 193 | 202 |
| Working Capital Days | 20 | 27 | 75 | 112 | 128 | 134 |
| ROCE % | 55% | 51% | 28% | 24% | 28% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
2d - Certificate under Regulation 74(5) of SEBI Depositories and Participants) Regulations 2018
- Closure of Trading Window 29 Sep
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
19 Sep - Anthem to attend JP Morgan India Investor Summit on Sept 22, 2025 in Mumbai.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
15 Sep - Anthem Biosciences: postal ballot resolutions approved, deemed passed Sept 12, 2025; scrutinizer report filed Sept 15, 2025.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
18 Aug - Earnings Call Transcripts for the Quarter ended June 30, 2025
Concalls
-
Aug 2025Transcript PPT REC
Business Overview:[1]
ABL is a Contract Research, Development,
and Manufacturing Organization with fully integrated operations across the drug discovery, development, and manufacturing value chain. It is among the few companies in India offering capabilities in both New Chemical
Entity (NCE) and New Biological Entity (NBE) programs. The company has developed various platforms such as RNA interference (RNAi),
Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides.